Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates

Verrica Pharmaceuticals (VRCA) delivered earnings and revenue surprises of +30.51% and +6.87%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Verrica Pharmaceuticals stock rises after partner launches YCANTH in Japan By Investing.com

Verrica Pharmaceuticals stock rises after partner launches YCANTH in Japan

Verrica Pharmaceuticals (VRCA) Upgraded to Strong Buy: Heres Why

Verrica Pharmaceuticals (VRCA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

How Much Upside is Left in Verrica Pharmaceuticals (VRCA)? Wall Street Analysts Think 97.11%

The mean of analysts price targets for Verrica Pharmaceuticals (VRCA) points to a 97.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Verrica Pharmaceuticals stock jumps after $50M financing deal By Investing.com

Verrica Pharmaceuticals stock jumps after $50M financing deal

Lucid Capital Markets initiates Verrica Pharmaceuticals stock with Buy rating By Investing.com

Lucid Capital Markets initiates Verrica Pharmaceuticals stock with Buy rating

Verrica Pharmaceuticals stock soars after Japan approves YCANTH By Investing.com

Verrica Pharmaceuticals stock soars after Japan approves YCANTH

Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates

Verrica Pharmaceuticals (VRCA) delivered earnings and revenue surprises of 28.57% and 22.82%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Heres Why Verrica Pharmaceuticals (VRCA) Is a Great Buy the Bottom Stock Now

Verrica Pharmaceuticals (VRCA) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stocks potential for a turnaround in the near term.

Verrica Pharmaceuticals, Inc. (VRCA) Q4 2024 Earnings Conference Call Transcript

Verrica Pharmaceuticals Inc. (VRCA) Reports Q4 Loss, Lags Revenue Estimates

Verrica Pharmaceuticals (VRCA) delivered earnings and revenue surprises of 4% and 80.78%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Verrica Pharmaceuticals Inc. (VRCA) Expected to Beat Earnings Estimates: Should You Buy?

Verrica Pharmaceuticals (VRCA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Lytix Biopharma AS – Licensing partner Verrica Pharmaceuticals presents clinical data with LTX-315 at the 2025 Winter Clinical Dermatology Conference

Oslo, Norway, January 22, 2025 – Lytix Biopharma’s licensing partner, Verrica Pharmaceuticals, has presented clinical data on Lytix lead drug candidate, LTX-315, at the 2025 Winter Clinical Dermatology Conference held January 17-19 in Miami, Florida. The results support a potential change in the treatment paradigm for patients with basal cell carcinoma. The three posters presented by Verrica at the conference highlighted positive clinical data from Part 2 of the Phase 2 study of LTX-315 (nam...

Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WEST CHESTER, Pa., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Verrica’s Compensation Committee granted David Zawitz, Verrica’s new Chief Operating Officer, a nonqualified stock option to purchase 950,000 shares of its common stock under the Company’s Inducement Plan, effective December 9, 2024. The sto...

Lytix Biopharma – Licensing partner Verrica Pharmaceuticals announces pricing of underwritten public offering, raising approximately USD 42 million upon completion

Oslo, November 21st 2024: Lytix Biopharma refers to the release made today by its licensing partner Verrica Pharmaceuticals, announcing the pricing of a USD 42 million underwritten public offering. The offering is expected to close on November 22, 2024, and the gross proceeds from the offering are expected to be approximately USD 42.0 million. Verrica also granted the underwriter an option for a period of 30 days to purchase up to 7,080,000 additional shares. The full announcement can be read ...

Verrica Announces Proposed Public Offering

WEST CHESTER, Pa., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it intends to offer and sell shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof) and in either case, accompanying warrants to purchase shares of its common stock, in an underwritten public offerin...

Lytix Biopharma Highlights Positive Data on LTX-315 in Collaboration with Verrica Pharmaceuticals at 2024 Fall Clinical Dermatology Conference

Oslo, Norway, October 24, 2024 - Lytix Biopharma, a Norwegian immuno-oncology company, today announces the acceptance of two abstracts showcasing positive preliminary topline results from Part 2 of the Phase II clinical study of LTX-315 (named VP-315 by Lytix’s licensing partner Verrica Pharmaceuticals) for the treatment of basal cell carcinoma (BCC). BCC is the largest skin cancer disease globally with a projected global market size of USD 11.5 bn in 2028 and 3.6 million new cases in the US ann...

Verrica Pharmaceuticals, Inc. (VRCA) Q2 2024 Earnings Call Transcript

PhII preliminary results from skin cancer clinical trial show an 86%overall reduction of tumor size, complete clearance in 51%of the patients and the potential to be utilized as a first-line therapy

Oslo, 14 August 2024. Lytix Biopharma (“Lytix”) announces that its Nasdaq-listed licensing partner Verrica Pharmaceuticals reports positive top-line Phase II results from its study in patients with basal cell carcinoma (BCC) - the largest skin cancer disease globally with a projected global market size of USD 11.5 bn in 2028 (CAGR 7.9%) and 3.6 million new cases in the US annually [1].  The study investigates Lytix’s lead drug candidate LTX-315 in BCC patients and shows impressively an: ·...

Lytix Biopharma: Lytix’s licensing partner, Verrica Pharmaceuticals, to release preliminary topline results from their Phase II trial of LTX-315 for the treatment of basal cell carcinoma on August 14

Oslo, August 06, 2024. Lytix Biopharma announces that its licensing partner, Verrica Pharmaceuticals, will host an investor call to report preliminary top-line data of its phase II study in patients with the skin cancer disease basal cell carcinoma on Wednesday, August 14 at 14:30 CET (included in Verrica’s presentation of its second quarter financial results). In this phase II study, Lytix’s lead drug candidate LTX-315 (named VP-315 in Verrica’s study) has been tested in basal cell carcinoma p...

Verrica Pharmaceuticals settles litigation with Dormer Labs By Investing.com

Verrica Pharmaceuticals settles litigation with Dormer Labs

Lytix Biopharma Q1 2024 results - Promising clinical progress with important upcoming milestones

Oslo, 30 May 2024. Lytix Biopharma (“Lytix”) (Euronext Growth Oslo: LYTIX), a Norwegian immuno-oncology company dedicated to being part of tomorrow’s cancer treatment, today releases its first quarter 2024 results. During the quarter, the company reached important clinical progress in two Phase II studies investigating its lead cancer drug candidate for two different types of skin cancer. Lytix`s licensing partner Verrica Pharmaceuticals achieved a complete patient enrollment in its Phase II...

VERRICA ALERT: Bragar Eagel & Squire, P.C. is Investigating Verrica Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, May 26, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Verrica Pharmaceuticals, Inc. (NASDAQ: VRCA) on behalf of long-term stockholders following a class action complaint that was filed against Verrica with a Class Period from May 28, 2021 to May 24, 2022. Our investigation concerns whether the board of directors of Verrica have breached their fiduciary duties to the company.

VERRICA ALERT: Bragar Eagel & Squire, P.C. is Investigating Verrica Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, May 17, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Verrica Pharmaceuticals, Inc. (NASDAQ: VRCA) on behalf of long-term stockholders following a class action complaint that was filed against Verrica with a Class Period from May 28, 2021 to May 24, 2022. Our investigation concerns whether the board of directors of Verrica have breached their fiduciary duties to the company.

Earnings call: Verrica Pharmaceuticals reports on Q1 2024 performance By Investing.com

Earnings call: Verrica Pharmaceuticals reports on Q1 2024 performance

Verrica Pharmaceuticals, Inc. (VRCA) Q1 2024 Earnings Call Transcript

Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024

WEST CHESTER, Pa., May 08, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, May 13, 2024 to provide a corporate update and discuss the Companys financial results for the first quarter ended March 31, 2024.

Verrica Pharmaceuticals (VRCA) Moves 7.4% Higher: Will This Strength Last?

Verrica Pharmaceuticals (VRCA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Bragar Eagel & Squire is Investigating Certain Officers and Directors of Caribou, Verrica, and Playstudios on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, April 27, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating certain officers and directors Caribou Biosciences, Inc. (NASDAQ: CRBU), Verrica Pharmaceuticals, Inc. (NASDAQ: VRCA), and Playstudios, Inc. (NASDAQ: MYPS) on behalf of long-term stockholders. More information about each potential case can be found at the link provided.

Earnings call: Verrica Pharmaceuticals reports progress with YCANTH By Investing.com

Earnings call: Verrica Pharmaceuticals reports progress with YCANTH